New York, USA – September 29, 2020 – Recently, two pharmaceutical giants have completed two blockbuster transactions involving ADC drugs. One is Gilead’s US$21 billion acquisition of Immunomedics that focuses on oncology, and the other is Merck and Seattle Genetics’ strategic cooperation project of ladiratuzumab vedotin for US$4.5 billion.
In 2019, with the approval of three ADC drugs (Polivy, Padcev, and Enhertu) by the FDA, ADC ushered in its outbreak period. An antibody-drug conjugate (ADC) is a combination of monoclonal antibody and small molecule cytotoxic drugs to improve the targeting of tumor drugs and reduce toxic side effects. Compared with traditional fully or partially humanized antibodies or antibody fragments, ADCs have theoretically higher therapeutic effects because they can release highly active cytotoxins in tumor tissues. As a reliable partner in the field of life science technology regarding pharmaceutical, Creative Biolabs keeps exploring the ADC area for over a decade and has accumulated rich experience and a good reputation.
Supported by a group of senior scientists, Creative Biolabs is offering comprehensive solutions for ADC discovery and high-standard ADC products. Based upon the DrugLnk service platform, a series of ADC linker products of high purity (95%) are developed, including ADC linkers and drug-linker complexes. The products are offered from milligrams to grams to meet with different research & development purposes.
As the basic building blocks of valid ADC, ADC linkers not only assist with the conjugation between antibodies with ADC toxins, they also dictate the release mechanism. Therefore, the right choice of the linker will elevate the chemical and serum stability of the resulting ADC more efficiently.
Pre-assembled drug-linker complexes are readily available for antibody conjugation, which can greatly expedite the development of ADCs. Chemically defined using the LC-MS and 1HNMR spectroscopy as they are, the complexes can fit in with customized ADC projects.
Featured services to support clients’ ADC projects are provided and can be customized upon requests, among which the linker module of DrugLnkTM custom synthesis can better accommodate individualized research projects by designing linkers made-to-order, including both cleavable linkers (e.g. pH-sensitive (acid-labile) linkers, disulfide linkers, protease-sensitive (peptide) linkers, ß-glucuronide linkers) and non-cleavable linkers.
ADC drugs can accurately identify the target and the non-cancer cells are not affected, which greatly improves the drug efficacy and reduces the toxic side effects, and has gained climbing attention in the biopharmaceutical field. With an increasing number of medicine manufacturers working on this powerful tool of target therapy, Creative Biolabs, a trustworthy CRO partner that can greatly improve and accelerate the entire process of ADC development projects is of vital importance.
More information about Creative Biolabs ADC customized solutions is available at https://www.creative-biolabs.com/adc.
About Creative Biolabs
Creative Biolabs is a CRO in the biotechnology industry, which is headquartered in New York and keeps providing conscientious services and high-standard products to global customers that are mainly pharmaceutical companies, research institutes, or universities. After years of exploration, scientists at Creative Biolabs have successfully established high-end technology platforms that enable the generation of ADC products and the process of ADC development projects. Dozens of successful cases and regular customers are proof of Creative Biolabs’ real strengths.